Pilot study explores low-dose rapamycin’s potential to slow ovarian aging, potentially extending fertility and improving women’s healthspan. Researchers at NewYork-Presbyterian/Columbia are investigating whether a weekly dose of rapamycin, one of longevity’s most talked-about drugs, can delay ovarian aging in women. Ovaries are one of the earliest-aging organs, and ovarian aging is considered the pacemaker of female body aging as it drives the aging of multiple organs of the body. Rapamycin has shown promise in animal studies, where it restored normal ovarian function in mice with premature ovarian failure and extended their reproductive lifespan. “Ovarian aging is the fundamental driver of aging in women,” she said.
